ReviewCancers2022
Natural Products/Bioactive Compounds as a Source of Anticancer Drugs.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
164 citing papers in PubMed, 2 syntheses or guidelines pooled it, 288 citations in OpenAlex.
- Natural products targeting the molecular pathology of salivary gland mucoepidermoid carcinoma: A systematic review of In vitro studies.Molecular biology reports · 2026Pooled it
- Joining up the scattered anticancer knowledge on auraptene and umbelliprenin: a meta-analysis.Scientific reports · 2024Pooled it
- Antitumor-Relevant Evaluation of Liquid and MicroencapsulatedMolecules (Basel, Switzerland) · 2026Article
- Chrysosplenetin-induced TMED3 aggregation triggers unfolded protein response in pancreatic cancer.EMBO molecular medicine · 2026Article
- Integrative multi-transcriptomics and network pharmacology reveal natural therapeutics as anti-cancer agents targeting AURKA for ovarian cancer treatment.Journal, genetic engineering & biotechnology · 2026Article
- Natural and Synthetic Compounds, Swords for Glioblastoma Therapy: From Tumor to Its Microenvironment.International journal of molecular sciences · 2026Review
- Antitumor properties of fungal-derived compounds: potential applications in skin cancer therapy.Molecular biology reports · 2026Review
- Isothiocyanates as Ferroptosis Inducers to Promote Cancer Cell Death.Phytotherapy research : PTR · 2026Review
- Pan-cancer multi-omics characterization of CDK12 and virtual screening of Vietnamese natural products for novel inhibitors.Molecular diversity · 2026Article
- Therapeutic Potential of Ginger Rhizomes (Zingiber officinale) on Leukemia.Biotechnology and applied biochemistry · 2026Review
- Thiram inhibits human sperm motility and capacitation by increasing mitochondrial OTranslational andrology and urology · 2026Article
- Natural Products in Cancer Research: Mechanistic Advances, Translational Challenges, and the Emerging Role of Chilean Biodiversity.Molecules (Basel, Switzerland) · 2026Review
- AC3Medical oncology (Northwood, London, England) · 2026Article
- Review
- Valorization of Moringa oleifera pericarp via semi-synthetic sugar-based enone derivatives with anticancer potential: phytochemical isolation, cytotoxic evaluation, and dual EGFR/CAIX targeting.Scientific reports · 2026Article
- Hydrogels Activated with Plant Extracts/Bioactive Compounds for Cancer Treatment: From Design to Application.Gels (Basel, Switzerland) · 2026Review
- Therapeutic Potential of Kuwanon G: From Bioactivities to Network-Level Mechanisms.Molecules (Basel, Switzerland) · 2026Review
- Natural Products as Modulators of ABC Transporters in Breast Cancer.Phytotherapy research : PTR · 2026Review
- Machine learning-assisted identification and validation of NRP1 inhibitors through molecular docking and dynamics simulations.Scientific reports · 2026Article
- Chlorination of Phenethyl Isothiocyanate Potentiates Cytotoxicity and Apoptosis in Multidrug-Resistant Leukemia Cells.International journal of molecular sciences · 2026Article
104 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 11 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the major deadly diseases globally. The alarming rise in the mortality rate due to this disease attracks attention towards discovering potent anticancer agents to overcome its mortality rate. The discovery of novel and effective anticancer agents from natural sources has been the main point of interest in pharmaceutical research because of attractive natural therapeutic agents with an immense chemical diversity in species of animals, plants, and microorganisms. More than 60% of contemporary anticancer drugs, in one form or another, have originated from natural sources. Plants and microbial species are chosen based on their composition, ecology, phytochemical, and ethnopharmacological properties. Plants and their derivatives have played a significant role in producing effective anticancer agents. Some plant derivatives include vincristine, vinblastine, irinotecan, topotecan, etoposide, podophyllotoxin, and paclitaxel. Based on their particular activity, a number of other plant-derived bioactive compounds are in the clinical development phase against cancer, such as gimatecan, elomotecan, etc. Additionally, the conjugation of natural compounds with anti-cancerous drugs, or some polymeric carriers particularly targeted to epitopes on the site of interest to tumors, can generate effective targeted treatment therapies. Cognizance from such pharmaceutical research studies would yield alternative drug development strategies through natural sources which could be economical, more reliable, and safe to use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.